ANDA 218473, held by Specgx LLC. Buprenorphine Hydrochloride.
As of Nov 16, 2026, ANDA 218473 (Buprenorphine Hydrochloride), held by Specgx LLC, was first approved by FDA on Dec 10, 2025, with 1 approved supplement and 0 published complete response letters.
Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 10, 2025 | Original application | Approved | None posted |
| Buprenorphine HydrochlorideEQ 2MG BASE · tablet;sublingual | Buprenorphine Hydrochloride | Rx |
| Buprenorphine HydrochlorideEQ 8MG BASE · tablet;sublingual | Buprenorphine Hydrochloride | Rx |
| Aug 14, 2026 | Supplement 3REMS | Approved | None posted |
| Dec 10, 2025 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters